Many pharma companies have begun shifting their R&D portfolios to the development of new cancer drugs. AstraZeneca recently announced a bold new cancer drug R&D portfolio strategy where the company will focus on early-stage cancers over late-stage (advanced) cancers for new drug development. This shift in focus goes against the standard target development paradigm where companies focus on drugs for late-stage cancers where patients and their oncologists have exhausted all available treatment options. This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R&D approach insights into this decision.
Complete the brief form to download the white paper.
Contact us at firstname.lastname@example.org with any questions.